[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2016-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FLT PET Imaging for Cervical Cancer

NCT01075412

Uterine Cervical Neoplasms

TERMINATED PHASE2

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

NCT01717391

Uterine Cervical Neoplasms Endometrial Neoplasms Anus Neoplasms +2 more

COMPLETED PHASE2

A Novel Functional Imaging Technique With FLT-PET/MRI For Staging, Response Assessment and Radiation Treatment Planning in Cervix Cancer

NCT05355558

Image, Body Cervix Cancer

UNKNOWN NA

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216

Breast Neoplasm Metastatic Breast Cancer Rb+ Breast Cancer

ACTIVE_NOT_RECRUITING PHASE1

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

NCT02139150

Histologically-confirmed Malignancies

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gynecologic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Proton subjects

[18F]Fluorothymidine (FLT) PET/CT Imaging

Intervention Type RADIATION

IMRT subjects

[18F]Fluorothymidine (FLT) PET/CT Imaging

Intervention Type RADIATION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]Fluorothymidine (FLT) PET/CT Imaging

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants will be 18 years of age or older
* History of gynecologic cancer.
* Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy
* Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit.
* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific procedures.
* Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.

Exclusion Criteria

* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study.
* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subjects safety or successful participation in the study.
* Unwilling or unable to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No